1st Feb 2016 09:14
LONDON (Alliance News) - Sareum Holdings PLC said Monday that it has submitted applications for phase I clinical trials of its development candidate cancer drug CCT245737 with the UK Medicines and Healthcare products Regulatory Agency.
The submissions trigger a GBP200,000 milestone payment from Cancer Research Technology Ltd.
Sareum has planned two clinical trials in cancer patients, one with CCT245737 as a single anti-cancer agency, and one in combination with standard-of-care chemotherapy.
"We are delighted to report a further significant step towards these two planned clinical trials with cancer patients and are very pleased to have earned this success milestone," said Chief Executive Officer Tim Mitchell in a statement.
Shares in Sareum were up 1.4% at 0.223 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Sareum